STOCK TITAN

[Form 4] Penumbra, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Penumbra Director Bridget O'Rourke reported a Form 4 filing disclosing the sale of 50 shares of common stock at a price of $259.78 per share on June 16, 2025. The transaction was executed under a pre-established Rule 10b5-1 trading plan, which provides a safe harbor from insider trading allegations.

Following the transaction, O'Rourke maintains beneficial ownership of 5,373 shares held directly, with a portion subject to vesting restrictions. The filing was submitted on June 28, 2025, within the required reporting timeframe.

  • Transaction Type: Sale of Common Stock
  • Total Transaction Value: $12,989
  • Ownership Form: Direct
  • Role: Director

Penumbra La direttrice Bridget O'Rourke ha comunicato una dichiarazione Form 4 riguardante la vendita di 50 azioni ordinarie a un prezzo di 259,78 $ per azione il 16 giugno 2025. L'operazione è stata effettuata nell'ambito di un piano di trading predefinito secondo la Regola 10b5-1, che offre una protezione contro accuse di insider trading.

Dopo la transazione, O'Rourke detiene la proprietà effettiva di 5.373 azioni possedute direttamente, con una parte soggetta a restrizioni di maturazione. La dichiarazione è stata presentata il 28 giugno 2025, entro i termini previsti per la segnalazione.

  • Tipo di transazione: Vendita di azioni ordinarie
  • Valore totale della transazione: 12.989 $
  • Forma di proprietà: Diretta
  • Ruolo: Direttrice

Penumbra La directora Bridget O'Rourke informó una presentación Formulario 4 que revela la venta de 50 acciones ordinarias a un precio de 259,78 $ por acción el 16 de junio de 2025. La transacción se realizó bajo un plan de negociación preestablecido según la Regla 10b5-1, que proporciona un refugio seguro contra acusaciones de uso de información privilegiada.

Tras la transacción, O'Rourke mantiene la propiedad beneficiaria de 5,373 acciones en posesión directa, con una parte sujeta a restricciones de consolidación. La presentación se realizó el 28 de junio de 2025, dentro del plazo requerido para reportar.

  • Tipo de transacción: Venta de acciones ordinarias
  • Valor total de la transacción: 12,989 $
  • Forma de propiedad: Directa
  • Rol: Directora

Penumbra 이사 Bridget O'Rourke는 2025년 6월 16일에 보통주 50주를 주당 259.78달러에 매도한 내용을 담은 Form 4 신고서를 제출했다고 보고했습니다. 이 거래는 내부자 거래 혐의로부터 안전한 보호를 제공하는 사전 설정된 Rule 10b5-1 거래 계획에 따라 이루어졌습니다.

거래 후 O'Rourke는 일부가 권리 확정 제한을 받는 5,373주를 직접 소유하고 있습니다. 신고서는 2025년 6월 28일에 요구된 보고 기간 내에 제출되었습니다.

  • 거래 유형: 보통주 매도
  • 총 거래 금액: 12,989달러
  • 소유 형태: 직접 소유
  • 직책: 이사

Penumbra La directrice Bridget O'Rourke a déclaré un dépôt Formulaire 4 révélant la vente de 50 actions ordinaires au prix de 259,78 $ par action le 16 juin 2025. La transaction a été exécutée dans le cadre d'un plan de négociation préétabli selon la règle 10b5-1, qui offre une protection contre les accusations d'initié.

Suite à la transaction, O'Rourke conserve la propriété bénéficiaire de 5 373 actions détenues directement, dont une partie est soumise à des restrictions d'acquisition. Le dépôt a été soumis le 28 juin 2025, dans le délai requis.

  • Type de transaction : Vente d'actions ordinaires
  • Valeur totale de la transaction : 12 989 $
  • Forme de propriété : Directe
  • Rôle : Directrice

Penumbra-Direktorin Bridget O'Rourke meldete eine Form-4-Einreichung, die den Verkauf von 50 Stammaktien zu einem Preis von 259,78 $ pro Aktie am 16. Juni 2025 offenlegt. Die Transaktion wurde im Rahmen eines vorab festgelegten Rule-10b5-1-Handelsplans durchgeführt, der einen sicheren Hafen vor Insiderhandelsvorwürfen bietet.

Nach der Transaktion hält O'Rourke weiterhin den wirtschaftlichen Eigentum an 5.373 Aktien, die direkt gehalten werden, wobei ein Teil Einschränkungen bezüglich der Vesting-Bedingungen unterliegt. Die Meldung wurde am 28. Juni 2025 innerhalb der vorgeschriebenen Meldefrist eingereicht.

  • Transaktionstyp: Verkauf von Stammaktien
  • Gesamtwert der Transaktion: 12.989 $
  • Eigentumsform: Direkt
  • Rolle: Direktorin
Positive
  • None.
Negative
  • None.

Penumbra La direttrice Bridget O'Rourke ha comunicato una dichiarazione Form 4 riguardante la vendita di 50 azioni ordinarie a un prezzo di 259,78 $ per azione il 16 giugno 2025. L'operazione è stata effettuata nell'ambito di un piano di trading predefinito secondo la Regola 10b5-1, che offre una protezione contro accuse di insider trading.

Dopo la transazione, O'Rourke detiene la proprietà effettiva di 5.373 azioni possedute direttamente, con una parte soggetta a restrizioni di maturazione. La dichiarazione è stata presentata il 28 giugno 2025, entro i termini previsti per la segnalazione.

  • Tipo di transazione: Vendita di azioni ordinarie
  • Valore totale della transazione: 12.989 $
  • Forma di proprietà: Diretta
  • Ruolo: Direttrice

Penumbra La directora Bridget O'Rourke informó una presentación Formulario 4 que revela la venta de 50 acciones ordinarias a un precio de 259,78 $ por acción el 16 de junio de 2025. La transacción se realizó bajo un plan de negociación preestablecido según la Regla 10b5-1, que proporciona un refugio seguro contra acusaciones de uso de información privilegiada.

Tras la transacción, O'Rourke mantiene la propiedad beneficiaria de 5,373 acciones en posesión directa, con una parte sujeta a restricciones de consolidación. La presentación se realizó el 28 de junio de 2025, dentro del plazo requerido para reportar.

  • Tipo de transacción: Venta de acciones ordinarias
  • Valor total de la transacción: 12,989 $
  • Forma de propiedad: Directa
  • Rol: Directora

Penumbra 이사 Bridget O'Rourke는 2025년 6월 16일에 보통주 50주를 주당 259.78달러에 매도한 내용을 담은 Form 4 신고서를 제출했다고 보고했습니다. 이 거래는 내부자 거래 혐의로부터 안전한 보호를 제공하는 사전 설정된 Rule 10b5-1 거래 계획에 따라 이루어졌습니다.

거래 후 O'Rourke는 일부가 권리 확정 제한을 받는 5,373주를 직접 소유하고 있습니다. 신고서는 2025년 6월 28일에 요구된 보고 기간 내에 제출되었습니다.

  • 거래 유형: 보통주 매도
  • 총 거래 금액: 12,989달러
  • 소유 형태: 직접 소유
  • 직책: 이사

Penumbra La directrice Bridget O'Rourke a déclaré un dépôt Formulaire 4 révélant la vente de 50 actions ordinaires au prix de 259,78 $ par action le 16 juin 2025. La transaction a été exécutée dans le cadre d'un plan de négociation préétabli selon la règle 10b5-1, qui offre une protection contre les accusations d'initié.

Suite à la transaction, O'Rourke conserve la propriété bénéficiaire de 5 373 actions détenues directement, dont une partie est soumise à des restrictions d'acquisition. Le dépôt a été soumis le 28 juin 2025, dans le délai requis.

  • Type de transaction : Vente d'actions ordinaires
  • Valeur totale de la transaction : 12 989 $
  • Forme de propriété : Directe
  • Rôle : Directrice

Penumbra-Direktorin Bridget O'Rourke meldete eine Form-4-Einreichung, die den Verkauf von 50 Stammaktien zu einem Preis von 259,78 $ pro Aktie am 16. Juni 2025 offenlegt. Die Transaktion wurde im Rahmen eines vorab festgelegten Rule-10b5-1-Handelsplans durchgeführt, der einen sicheren Hafen vor Insiderhandelsvorwürfen bietet.

Nach der Transaktion hält O'Rourke weiterhin den wirtschaftlichen Eigentum an 5.373 Aktien, die direkt gehalten werden, wobei ein Teil Einschränkungen bezüglich der Vesting-Bedingungen unterliegt. Die Meldung wurde am 28. Juni 2025 innerhalb der vorgeschriebenen Meldefrist eingereicht.

  • Transaktionstyp: Verkauf von Stammaktien
  • Gesamtwert der Transaktion: 12.989 $
  • Eigentumsform: Direkt
  • Rolle: Direktorin
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
O'Rourke Bridget

(Last) (First) (Middle)
ONE PENUMBRA PLACE

(Street)
ALAMEDA CA 94502

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Penumbra Inc [ PEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/16/2025 S(1) 50 D $259.78 5,373(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
2. A portion of these shares is subject to vesting.
Remarks:
/s/ Johanna Roberts, as attorney-in-fact for Bridget O'Rourke 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of PEN stock did Director Bridget O'Rourke sell on June 16, 2025?

Director Bridget O'Rourke sold 50 shares of Penumbra Inc (PEN) common stock at a price of $259.78 per share on June 16, 2025.

How many shares of PEN does Bridget O'Rourke own after the June 2025 transaction?

Following the reported transaction, Bridget O'Rourke beneficially owns 5,373 shares of Penumbra Inc (PEN) stock directly, with a portion of these shares subject to vesting.

Was PEN Director O'Rourke's stock sale part of a 10b5-1 trading plan?

Yes, according to the Form 4 filing, the sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, as noted in the explanation of responses.

What is Bridget O'Rourke's role at PEN according to the Form 4?

According to the Form 4 filing, Bridget O'Rourke serves as a Director of Penumbra Inc (PEN), as indicated by the 'X' marked in the Director box under the relationship section.
Penumbra Inc

NYSE:PEN

PEN Rankings

PEN Latest News

PEN Latest SEC Filings

PEN Stock Data

9.95B
37.36M
3.93%
92.35%
3.52%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
ALAMEDA